The investment round was led by Forbion Capital Partners.
The funding will be used to advance the company’s lead product, EG-12, into clinical trials. EG-12 is a carrier-DNA complex designed for the treatment of ulcerative colitis. The product aims to produce intestinal-localized expression of anti-inflammatory cytokine IL-10, according to the report.
“The unique technology of enGene effectively turns the gut into a protein factory, and given the strong genetic relation between IL-10 and ulcerative colitis, we expect EG-12 to provide significant benefit to IBD patients,” said Forbion managed partner Sander van Deventer, MD, PhD.
More articles on gastroenterology:
What do GI fellows need to know before establishing a practice?
AGA addresses duodenoscope infection risks
Bill requiring payers to cover CRC screening introduced in Kentucky
